Founders

Dr. Hanlee Ji, MD
Co-Founder, Scientific and Medical Advisor

Dr. Ji is Assistant Professor of Oncology, Department of Medicine, Stanford University School of Medicine. Hanlee is a respected worldwide leader in the field of genomic analysis and genomic technologies including next generation sequencing. Dr. Ji’s research has been the recipient of NIH funding in cancer genomics, technology development, and cancer genetics. He is recipient of numerous awards including a Howard Hughes Physician Scientist fellowship and a NIH K-08 award focused on colorectal cancer development. Hanlee holds a BA in Biology from Reed College and an MD from Johns Hopkins University. He is certified in internal medicine and medical oncology. He successfully completed training in clinical genetics and has held faculty positions at the University of Washington and Stanford University.

Dr. Lincoln Nadauld, MD, PhD
Co-Founder, Director, Scientific and Medical Advisor

Dr. Nadauld is a medical oncologist and Director of Cancer Genomics at Intermountain Health Care. Dr. Nadauld is an Adjunct Assistant Professor of Oncology, Department of Medicine, Stanford University School of Medicine. Dr. Nadauld holds a BA from Brigham Young University and an MD and PhD from the University of Utah where he also completed his residency training in internal medicine. His clinical oncological training was completed at Stanford University. Lincoln has published extensively in peer-reviewed scientific and medical journals including Journal of Biological Chemistry, PNAS, and Journal of Clinical Oncology. His previous ventures include Zicthus Therapeutics, which was launched out of the University of Utah and focuses on novel WNT-targeted therapeutics.

Dr. James M. Ford, MD
Co-Founder, Scientific and Medical Advisor

Dr. Ford is Associate Professor of Oncology and Genetics, Department of Medicine, Stanford University School of Medicine. Dr. Ford holds a BA (magna cum laude) and an MD from Yale University. He completed residency, fellowship and postdoctoral training at Stanford University. His expertise in the field of genetics has led to multiple editorial board positions for highly respected peer-review journals including Cancer Research, DNA Repair, and PLOS Genetics. His research is the subject of multiple NIH awards with repeated renewals. He continues to lead the field of genetics and oncology in his role on the NCCN guidelines committee for colorectal cancer screening and high-risk genetics. As an Associate Professor at Stanford, he has successfully led multiple clinical trials evaluating novel cancer therapeutics in phase I and phase II stages.

Dr. Calvin J. Kuo, MD, PhD
Co-Founder, Scientific Advisor

Dr. Kuo is Professor of Hematology, Department of Medicine, Stanford University School of Medicine. Dr. Kuo is a leader in the field of cancer biology and is generally considered one of the premier oncological physician-scientists in the world. His research has received numerous large grants from the NIH, NCI and various prestigious private foundations. Calvin holds a BA in biochemistry from Harvard and an MD and PhD from Stanford. He has received numerous awards including a Howard Hughes Medical Institute Fellowship, Investigator Awards from the Burroughs Wellcome and Kimmel Foundations, and election to the American Society for Clinical Investigation. Dr. Kuo has the distinction of serving as the Research Committee Chair for the NIH Intestinal Stem Cell Consortium. He is consistently named to various NIH study sections and as a reviewer to major medical journals including Nature, Nature Medicine, PNAS, and Blood. His insight and creativity have led to numerous important advances in the fields of hematology and oncology, resulting in multiple patent applications, two of which are licensed by this company.